| Pair Name | Beta-Elemene, Erlotinib | ||
| Phytochemical Name | Beta-Elemene (PubChem CID: 6918391 ) | ||
| Anticancer drug Name | Erlotinib (PubChem CID: 176870 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Beta-Elemene, Erlotinib | |||
| Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
| Biological Phenomena | Induction-->Ferroptosis | |||
| Gene Regulation | Up-regulation | Expression | H19 | KEGG ID N.A. |
| In Vitro Model | NCI-H1975 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1511 |
| NCI-H1650 | Minimally invasive lung adenocarcinoma | Homo sapiens (Human) | CVCL_1483 | |
| NCI-H1819 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_1497 | |
| In Vivo Model | 5×10⁶ H1975 shRNA-NC cells or H1975 H19-shRNA cells were injected subcutaneously into 6-week-old female nude mice in the right flanks. | |||
| Result | Our data showed that β-elemene combined with erlotinib could enhance sensitivity to EGFR-TKIs through induction of ferroptosis via H19 in primary EGFR-TKI-resistant lung cancer, providing a promising strategy to overcome EGFR-TKI resistance in NSCLC patients. | |||
| No. | Title | Href |
|---|---|---|
| 1 | β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer. Pharmacol Res. 2023 May;191:106739. doi: 10.1016/j.phrs.2023.106739. | Click |
